What AC Immune SA does.

AC Immune is a leading, clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. Our highly differentiated approach aims to overcome the fundamental challenge in this therapeutic area – the high number of co-pathologies driving disease development and progression and the urgent need for more tailored therapeutic regimens.

Leveraging our dual proprietary technology platforms, SupraAntigen and Morphomer, we have built a comprehensive pipeline of first-in-class or best-in-class candidates spanning multiple treatment modalities and targeting both established and emerging neurodegenerative pathologies. We are currently advancing therapeutic programs targeting multiple pathologies related to Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. Our pipeline assets are further validated by the multiple partnerships we have established with leading global pharmaceutical companies. We believe our clinically validated technology platforms and multi-target, multimodal approach will enable AC Immune to revolutionize the treatment paradigm for neurodegenerative disease by shifting it towards Precision Medicine and disease prevention.

Revenue and profit, by fiscal year.

More on ACIU.

• AC Immune SA summary
• AC Immune SA financial statements
• AC Immune SA key metrics
• AC Immune SA health scores and style box
• AC Immune SA earnings
• AC Immune SA dividends
• AC Immune SA valuation
• AC Immune SA ownership and insiders
• AC Immune SA peers

Figures from AC Immune SA's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.